Human Interferon-Induced Double Stranded RNA-Activated Protein Kinase (EIF2AK2) Protein

Product Graph
832€ (50 µg)

Por favor contáctenos para obtener información detallada sobre el precio y disponibilidad.

935106861
info@markelab.com
name
Human Interferon-Induced Double Stranded RNA-Activated Protein Kinase (EIF2AK2) Protein
category
Proteins and Peptides
provider
Abbexa
reference
abx651433
tested applications
WB, SDS-PAGE

Description

Human Interferon-Induced Double Stranded RNA-Activated Protein Kinase (EIF2AK2) Protein (Active) is a recombinant active Human protein expressed in E. coli.

Documents del producto

Instrucciones
Data sheet
Descargar

Product specifications

Category
Proteins and Peptides
Immunogen Target
Interferon-Induced Double Stranded RNA-Activated Protein Kinase (EIF2AK2)
Host
E. coli
Assay Type
Activity: Active
Biological Activity: Protein Kinase R (PKR) is activated by double-stranded RNA (dsRNA), the synthesis of which is caused by viruses. PKR can also be activated by the protein PACT or by heparain. It plays a key role in the innate immune response to viral infection and is also involved in the regulation of signal transduction, apoptosis, cell proliferation and differentiation. Cyclin Dependent Kinase 1 (CDK1) has been identified as an interactor of PKR, thus a binding ELISA assay was conducted to detect the interaction of recombinant human PKR and recombinant human CDK1. Briefly, PKR was diluted serially in PBS with 0.01% BSA (pH 7.4). Duplicate samples of 100 μl were then transferred to CDK1-coated microplate wells and incubated for 2 h at 37°C. Wells were washed with PBST and incubated for 1 h with anti-PKR polyclonal antibody, then aspirated and washed 3 times. After incubation with HRP-conjugated secondary antibody, wells were aspirated and washed 3 times. TMB substrate solution was added and wells were incubated for 15-25 minutes at 37 °C. Finally, 50 μl stop solution was added to the wells and the absorbance was read at 450 nm immediately. 
Sequence Fragment: Ser224-Ile502
Tag: N-terminal His tag
Origin
Human
Conjugation
Unconjugated
Observed MW
Calculated MW: 35.8 kDa  Observed MW: 32 kDa  Possible reasons why the actual band size differs from the predicted band size: 1. Splice variants. Alternative splicing may create different sized proteins from the same gene. 2. Relative charge. The composition of amino acids may affect the charge of the protein. 3. Post-translational modification. Phosphorylation, glycoslyation, methylation etc. may affect the band size. 4. Post-translational cleavage. Many proteins are synthesised as pro-proteins, and then cleaved to give the active form. 5. Polymerisation of the target protein. Dimerisation, multimerisation etc. will increase the band size observed.
Expression
Recombinant
Purity
> 80%
Size 1
50 µg
Size 2
100 µg
Size 3
200 µg
Size 4
500 µg
Size 5
1 mg
Form
Lyophilized
Tested Applications
WB, SDS-PAGE
Buffer
Prior to lyophilization: 20 mM Tris, 150 mM NaCl, pH 8.0, containing 0.01% Sarcosyl, 5% Trehalose.
Availability
Shipped within 5-7 working days.
Storage
Store lyophilized form at 2-8°C for up to 1 month. For longer periods, store lyophilized or liquid at -80°C. Avoid repeated freeze–thaw cycles.
Dry Ice
No
UniProt ID
P19525
Background
Protein EIF2AK2
Status
RUO
Note
THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC, THERAPEUTIC OR COSMETIC PROCEDURES. NOT FOR HUMAN OR ANIMAL CONSUMPTION.
Reconstitute in ddH2O to a concentration between 0.1-1.0 mg/ml. Do not vortex.
Endotoxin Level: < 1.0 EU/µg (LAL method)
Concentration: Prior to lyophilization: 200 µg/ml

Descripción

Related Products

EH1291

Human EIF2AK2 (Interferon-induced, double-stranded RNA-activated protein kinase) ELISA Kit

Ver Producto
FNab02691

EIF2AK2 antibody

Ver Producto
P2445

Recombinant Human EIF2AK2

Ver Producto